Acer Medical Inc. (6857) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Acer Medical Inc. TWD 10.38, price TWD 90.20, upside -88.5%, quality 50 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Acer Medical Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Acer Medical Inc. offers artificial intelligence, clinical data, and software for healthcare sector.
Show more
Acer Medical Inc. offers artificial intelligence, clinical data, and software for healthcare sector. It offers VeriSee DR, an AI-assisted diagnostic software for diabetic retinopathy identification; VeriSee AMD, an AI-assisted screening software for age-related macular degeneration identification; and VeriOsteo OP, an AI-assisted screening software for bone mineral density abnormalities. Acer Medical Inc. was founded in 2018 and is based in New Taipei City, Taiwan.
Stock analysis
Acer Medical Inc. (6857) currently trades at 90.20 TWD, while our model-based Fair Value estimate is 10.38 TWD, 88.5% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 6.85 TWD (bear) to 12.98 TWD (bull), the price of 90.20 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Acer Medical Inc. reported revenue of 60.1M TWD in FY2025 versus 9.6M TWD in FY2021, a compound +58.0%/yr. Reported net income was −29.7M TWD in FY2025.
Key figures
Market cap 1.4B TWD (≈ $43.2M) · P/S ratio 23.5 · EPS (TTM) −1.95 TWD · Net margin −49.4% · Return on equity −16.5% · Return on assets (EBIT) −15.8% · Operating margin −53.9% · Revenue (TTM) 60.1M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −88%, 6857 screens richer than that median.
Fair Value models
Bear 6.85 TWDFair Value 10.38 TWDBull 12.98 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+19.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+66.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+126.2%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,185.2% (2020) → −54.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 116 stocks
Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside−88.5% · Bottom 25%
Profitability
Return on assets−9.4% · Bottom 25%
Net margin (TTM)−49.4% · Bottom 25%
Operating margin (TTM)−53.9% · Bottom 25%
Growth and dividend
Revenue growth19.8% · Above median
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/B0.26× · Cheapest 25%
P/S (TTM)0.72× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)99· sector 48
PAST (return on equity)0· sector 12
HEALTH (low debt)0· sector 98
DIVIDEND (yield)0· sector 44
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Acer Medical Inc. Fair Value". https://www.fairvalue-calculator.com/stock/6857
Frequently asked questions
Is Acer Medical Inc. (6857) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 10.38 TWD versus a price of 90.20 TWD, about −88% upside (overvalued).
What is the fair value of 6857?
Our model-based fair value for Acer Medical Inc. is 10.38 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 90.20 TWD.
What is the quality score of 6857?
Acer Medical Inc. has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Acer Medical Inc. (6857)?
Our model-based price target is the fair value of 10.38 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 6.85 TWD, optimistic scenario 12.98 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Acer Medical Inc. stock forecast for 2026?
Our models put fair value at 10.38 TWD, about −88% upside versus a price of 90.20 TWD (overvalued). Cautious scenario 6.85 TWD, optimistic scenario 12.98 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Acer Medical Inc. (6857)?
Acer Medical Inc. reported trailing-twelve-month revenue of about 60.1M TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Acer Medical Inc. (6857)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Acer Medical Inc. it is 10.38 TWD per share (as of Sep 24, 2026), against a price of 90.20 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Acer Medical Inc. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6857 trades above its calculated fair value: price 90.20 TWD, fair value 10.38 TWD, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6857?
No. The price is what the market pays today (90.20 TWD); the fair value is what the company's own numbers justify (10.38 TWD). For Acer Medical Inc. the two are 79.82 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Acer Medical Inc. worth?
The market values Acer Medical Inc. at about 1.4B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 90.20 TWD; our models calculate a fair value of 10.38 TWD per share.
What do the bullish and bearish scenarios say about 6857?
Our models span a range for Acer Medical Inc.: cautious scenario 6.85 TWD, base 10.38 TWD, optimistic 12.98 TWD per share (as of Sep 24, 2026, price 90.20 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Acer Medical Inc. (6857)?
Balance-sheet figures for Acer Medical Inc. (as of Sep 24, 2026): return on equity −16.5%. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
Which stocks are comparable to Acer Medical Inc.?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Acer Medical Inc. stock attractive at the current price?
The data as of Sep 24, 2026: price 90.20 TWD, calculated fair value 10.38 TWD (−88%), Quality Score 50/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6857 calculated?
We run Acer Medical Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 10.38 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Acer Medical Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Acer Medical Inc. (6857)?
The closing price on Oct 2, 2026 was 90.20 TWD. Our model-based fair value is 10.38 TWD, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Acer Medical Inc. right now?
The price sits above even our optimistic bull case (12.98 TWD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (6.85 TWD to 12.98 TWD) leaves room in how you read the outcome.
Key figures of Acer Medical Inc.
How large is the market capitalisation of Acer Medical Inc. (6857)?
The market capitalisation of Acer Medical Inc. is 1.4B TWD (≈ $43.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Acer Medical Inc. (6857)?
The price-to-sales ratio of Acer Medical Inc. is 23.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Acer Medical Inc. (6857)?
Earnings per share at Acer Medical Inc. are −1.95 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Acer Medical Inc. (6857)?
The net margin of Acer Medical Inc. is −49.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Acer Medical Inc. (6857)?
The return on equity (ROE) of Acer Medical Inc. is −16.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Acer Medical Inc. (6857)?
On an EBIT basis the return on assets of Acer Medical Inc. is −15.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Acer Medical Inc. (6857)?
The operating margin of Acer Medical Inc. is −53.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Acer Medical Inc. (6857)?
Revenue at Acer Medical Inc. is growing +19.8% versus a year earlier (3y avg +66.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Acer Medical Inc. (6857) generate?
The free cash flow of Acer Medical Inc. is −25.7M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Acer Medical Inc. (6857) hold?
Acer Medical Inc. holds more cash than debt, 203M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Acer Medical Inc. in the live analysis
One click puts Acer Medical Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
